European clinical AI products are starting to compete not only on answer quality, but on regulatory posture, professional-use boundaries, and evidence traceability. DR.INFO is a useful case study because it makes all three visible.
Why CE-Marked Medical AI Is Becoming a Market Signal
In the US market, clinical AI tools compete primarily on adoption, model power, and integration — OpenEvidence on physician scale, ChatGPT for Clinicians on GPT-5 capability, DoxGPT on physician network distribution. Regulatory status is rarely the leading differentiator.
In Europe, the picture is different. The EU AI Act classifies certain AI systems as high-risk, with corresponding requirements for conformity assessment, risk management, and post-market surveillance. The EU Medical Device Regulation (MDR 2017/745) applies to software that qualifies as a medical device — including software intended to provide information used in clinical decision-making.
Against this backdrop, CE marking has become a competitive signal. It tells clinicians and procurement teams that a product has been assessed against MDR requirements — including risk management, clinical evaluation, and quality management systems. It does not guarantee clinical superiority or answer quality, but it does provide a governance framework that unregulated tools lack.
What DR.INFO Publicly Says About Its Regulatory Status
DR.INFO states that it is CE-marked under EU MDR 2017/745, hosted within the EU, and GDPR-aligned. It also claims compliance with the EU AI Act and HIPAA. The platform is operated by Synduct GmbH in Munich.
These are public claims on DR.INFO's website and legal notice. They position the product within the European regulatory framework rather than outside it — a deliberate competitive choice in a market where OpenEvidence has withdrawn from the EU/UK and ChatGPT's health products have no medical device registration anywhere.
Why Product Labels Matter More Than Marketing Pages
DR.INFO's marketing describes it as a clinical AI assistant that helps physicians access medical knowledge. Its product label — the regulatory document that defines the product's intended purpose under MDR — is more precise.
The product label describes DR.INFO as an informational and educational software device for qualified healthcare professionals. It explicitly states that DR.INFO is not to be used to inform diagnosis, treatment, or medical decision-making, and is not intended for emergency or time-critical decisions. The label warns that AI-generated outputs may introduce summarisation errors and that outputs must be independently reviewed and verified by the responsible healthcare professional.
This distinction matters for clinicians. The marketing phrase "clinical AI" can describe tools with very different intended purposes. A tool intended for information and education operates within a different regulatory boundary than a tool intended for clinical decision support. Both can be useful. But clinicians should know which boundary applies to the tool they are using — and what that means for how they should verify its outputs.
The Difference Between Clinical Reference and Clinical Decision-Making
This is not just a DR.INFO point — it applies across the entire clinical AI category.
A clinical reference tool retrieves and presents information for the clinician to interpret. The clinician makes the decision; the tool provides the information. The regulatory burden is lower because the tool does not claim to influence clinical decisions directly.
A clinical decision support tool provides recommendations or prompts that influence clinical decisions. The regulatory burden is higher — the tool's outputs directly affect patient care, and the manufacturer must demonstrate that those outputs are safe and effective.
Both categories are useful. But they carry different governance implications, different liability structures, and different expectations for how clinicians interact with them. When evaluating any clinical AI tool, clinicians should check the product label — not just the marketing page — to understand what the manufacturer says the tool is designed to do.
What UK Clinicians Should Look For in Any Medical AI Tool
For UK clinicians, the practical question is broader than regulatory language alone. Does the tool provide checkable answers with visible citations? Does it fit UK practice — citing NICE, CKS, BNF, and SIGN rather than international guidelines that may not apply to UK patients? Does it support the real clinical tasks doctors perform every day — from quick guideline checks to exam preparation to clinical scoring?
iatroX is built around that practical UK clinician workflow: cited clinical answers, calculators, exam preparation, and ongoing learning. UKCA-marked, MHRA-registered. The regulatory governance is there — but the daily usefulness is what earns repeated clinician use.
Try Ask iatroX for UK-focused clinical questions, calculators, and exam preparation →